Prof. Bedke stated, “Overall survival (OS) and disease-free survival (DFS) can be prolonged with this neoadjuvant approach. Furthermore, in terms of drugs, immunotherapy combinations seem to be very favourable. However, we can only use what is approved or what is available in the metastatic setting, where we have data on efficacy. The NESCIO trial which demonstrated the efficacy of nivolumab + ipilimumab combination.”

According to Prof. Bedke when discussing surrogate markers, “Imaging such as a conventional CT scan is poor with no good correlation.” In terms of pathology, its importance in the definition of pathological complete response (pCR) or nearly pCR of less than 10% viable tumour cells; and to assess and correlate them. In addition, he pointed out that a biomarker of molecular disease is missing.

During his presentation, he also discussed trials such as aforementioned NESCIO, NIAGARA, IMvigor011, and KEYNOTE-905.

(Re)watch his presentation on the EMUC25 Resource Centre.

The post Neoadjuvant treatment strategies in 2025 appeared first on EMUC25.

Report: The Big PCa game-changers for 2025!

In an auditorium packed to capacity, the ‘Game-changing’ session today offered a concise wrap-up of an exceptional year in oncology research, particularly for prostate cancer patients. Read this report summarising the presentations on PSMAddition, AMPLITUDE, CAPItello-281, and EMBARK results.

—

Webcasts of the day

CREST
T. Powles, London (GB)

CC Case: Systemic treatment for RCC – What to do with the primary tumour? Take it out or let the drug do the work?
U.  Vogl, Bellinzona (CH), G.  Pignot, Marseille (FR), and Y.  Ürün, Ankara (TR)

—

Report: Hereditary GU cancers session examines BRCA and PRS

Is prostate cancer (PCa) risk elevated in individuals with BRCA mutations? What is the potential of polygenic risk score (PRS) in PCa screening? Experts explored these topics during “Plenary Session 8: Hereditary genito-urinary cancers” held on day 3 of EMUC25.

—

Photos from the congress floor in Prague

Check out our photo albums of Day 3 of EMUC25 and Abstract Award winners on Facebook. Share your photos and stories on Instagram, LinkedIn, and X as well.

—

Best EMUC25 Abstracts

O04: Real world evidence of adjuvant pembrolizumab in renal cell carcinoma (RCC) from a Spanish registry: The ARENAL trial from the GUARD consortium.
M.I. Galante Romo, Madrid (ES)

O01: ONE SHOT – single shot radiotherapy for localized prostate cancer: primary endpoint results of a single arm, multicenter, prospective phase I/II trial
T. Zilli, Bellinzona (CH)

O03: Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide plus leuprolide (enza combo): EMBARK post hoc analysis
A.S. Rannikko, Espoo (FI)

The post Highlights from Day 3 appeared first on EMUC25.

For ctDNA-positive patients, adjuvant immunotherapy can be offered, with demonstrated treatment efficacy in a predominantly clinically high-risk population (IMvigor011), and a 50% ctDNA clearance in both low- and high-risk groups (TOMBOLA).

Prof. Dyrskjøt: “Overall, ctDNA-based molecular stratification outperforms clinical and histopathological risk assessment in identifying patients who benefit from adjuvant treatment, as shown in both IMvigor011 and TOMBOLA.”

In regard to the requirements for implementing ctDNA-guided care, Prof. Dyrskjøt stated that “Sensitive tumour-informed tests are required. Continued ctDNA analysis is needed, a single test post-RC is not enough, and assay availability and fast turnabout time are essential. We need to generate knowledge on how to bridge and use ctDNA in the peri-operative setting (NIAGARA, KEYNOTE-905/EV303, etc.).”

On his overall view on ctDNA use, he concluded, “Yes, it can be used for guiding adjuvant immunotherapy. But for guiding pre-cystectomy treatment – no, not yet; we need more studies first.”

Following this was a presentation on ‘Treating metastatic bladder cancer when money is an issue’, by Dr. Jorge Estaban Villarrubia (ES). “Back in October 2023, we were all excited about the enfortumab -vedotin + prembrolizunam (EV-P) data presented, and then the 2024 guidelines were updated and the EMA granted approval for the new combination.”

But according to Dr. Estaban Villarrubia, it is important to note that although the survival rates of this combination therapy are impressive, its high-cost limits broader use in many public health settings. In addition, some countries (including Spain) are still awaiting approval of EV-P, and there is also the issue of access to NGS (next-generation sequencing) which is not readily available in all hospitals.

“As oncologists, we must ask some important questions when we can’t get the best systemic therapy. What are the next best options for maximising treatment benefit, without increasing toxicity? Is there a role for radical treatment options?”

He reviewed treatments such as chemotherapy (cisplatin), split dose cisplatin for cisplatin-ineligible symptomatic patients, as well as strategies supported by evidence to reduce the number of cycles in order to minimise toxicity.

In his take-home messages, he concluded, “When money is an issue, we still have therapeutic options with proven efficacy. Collaboration between institutions is key to providing access to precision medicine, clinical trials and best available care. Multidisciplinary management of the patient leads to better outcomes, not only in survival, but quality of life, too. We must not forget that palliation is an important target of our treatment.”

For more information, you can (re)watch the presentations via the EMUC25 Resource Centre.

The post Treatment challenges in MIBC: ctDNA, EV-P cost and access appeared first on EMUC25.

On BRCA mutations

In her presentation on BRCA, medical oncologist and EMUC25 Steering Committee member Dr. Elena Castro (ES) stated that lifetime prostate cancer (PCa) risk is significantly elevated in individuals with BRCA mutations, with estimates of approximately 17% for BRCA1 carriers and up to 40% for those with BRCA2. Due to this higher risk, annual PSA screening beginning at age 40–45 is recommended for BRCA2 mutation carriers. In contrast, there is currently no clearly established screening ESMO guideline for individuals with BRCA1 mutations.

Germline BRCA2 is considered an adverse prognostic factor in PCa, while the impact of BRCA1 is less well defined. Patients with PCa who harbour BRCA1 or BRCA2 mutations benefit from close clinical monitoring. Importantly, germline BRCA1 and BRCA2 alterations sensitise tumours to PARP inhibitors.

Men with high-risk localised, locally advanced, or metastatic PCa should be offered germline genetic testing. Currently, there are no clinical characteristics to identify mutation carriers. Dr. Castro added that when a BRCA1 or BRCA2 mutation is detected in tumour tissue, germline origin should be excluded.

PRS for PCa screening

In her presentation “Polygenic risk to guide prostate cancer screening”, oncogenetics research nurse consultant Dr. Elizabeth Bancroft (GB) discussed the potential of using PRS in PCa screening.

PRS is used to estimate an individual’s genetic predisposition to developing a certain disease. However, it only provides the probability, not a prediction. A higher PRS means a higher genetic predisposition to the disease relative to others in the population, and it can be used to risk-stratify populations.

PRS is calculated by summing the effects of single nucleotide polymorphisms (SNPs), which are the most common type of genetic variation among people. There are 451 SNPs identified that are associated with PCa.

Dr. Bancroft discussed the BARCODE1 study, which evaluated the use of PRS (~130 SNPs) to identify those at the highest risk. Those participants in the top 10% were offered PSA, MRI, and prostate biopsy. The BARCODE1 study concluded that PRS found a high proportion of clinically significant PCa in men at higher genetic risk. PSA and MRI missed some significant cancers in this high-risk group.

“PRS is a one-time test using germline DNA, which is constant, unlike other tools such as PSA, which can fluctuate,” stated Dr. Bancroft.

Furthermore, the PRODICT study, which will replicate BARCODE1, was recently launched with an enriched recruitment in Black African, Black Caribbean, East Asian and South Asian populations.

Pathologist Prof. Markus Eckstein (DE), urologist Prof. Juan Gómez Rivas (ES), oncologist Dr. Pasquale Rescigno (GB), radiation oncologist Dr. Noelia Sanmamed (ES), and radiologist Prof. Harriet Thoeny (CH) spearheaded the session.

For more information, you can (re)watch the presentations via the EMUC25 Resource Centre.

The post EMUC25 examines BRCA and PRS in hereditary GU cancers session appeared first on EMUC25.

PSMAddition

Medical oncologist Prof. Scott Tagawa (US) presented the interim analysis of PSMAddition, a phase III trial of ¹⁷⁷Lu-PSMA-617 combined with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Tagawa: “The addition of ¹⁷⁷Lu-PSMA-617 with ADT and ARPI led to a statistically significant improvement in radiographic progression-free survival (rPFS) in patients with PSMA-positive mHSPC, compared to ADT + ARPI. This benefit was consistent across subgroups. There was a positive trend in overall survival (OS), with follow-up for mature data ongoing. The results of the PSA response, PFS, mCRPC, and symptomatic skeletal events (SSE) favoured the ¹⁷⁷Lu-PSMA-617 combination arm.”

In regard to safety, Dr. Tagawa said that findings where consistent with the known profile of ¹⁷⁷Lu-PSMA-617, with no unexpected concerns about the combination with ADT + ARPI. “Adverse events were more frequent in the ¹⁷⁷Lu-PSMA-617 combination arm, most commonly dry mouth, fatigue, and nausea. There were no clinically significant differences in time worsening in health-related quality of life.”

He concluded that the PSMAddition trial findings indicate that combining ¹⁷⁷Lu-PSMA-617 with ADT and ARPI provides a clinically meaningful benefit in patients with PSMA-positive mHSPC.

AMPLITUDE

“This trial is a good example of molecular precision medicine.” Began Dr. Gerhardt Attard (GB) in his presentation on the phase 3 AMPLITUDE trial results: niraparib + abiraterone acetate + prednisone for metastatic castration-sensitive prostate cancer (mCSPC) patients with alterations in homologous recombination repair genes.

Dr. Attard: “The AMPLITUDE trial met its primary endpoint of improved rPFS, with the likely greatest benefit of the combination treatment in patients with BRCA alterations (HR: 0.52). Improvements in rPFS were supported by a statistically significant delay in time to symptomatic progression and a trend toward improved overall survival. There was less than 5% increase in patients discontinuing treatment due to toxicity compared to the placebo.”

He also noted that treatment intensification requires careful patient selection due to the associated increase in toxicity.

He concluded that the AMPLITUDE results support early genomic testing, and niraparib + abiraterone acetate + prednisone as a new treatment option for patients with mHSPC and HRR gene alterations.

CAPItello-281

Dr. Gerhardt Attard (GB) also presented the phase III study of capivasertib + abiraterone versus placebo + abiraterone in patients with PTEN-deficient de novo mHSPC, an important advancement given that these patients typically have a poor prognosis and limited benefit from the current standard-of-care therapy.

From the results he presented, the CAPItello-281 trial met its primary objective, showing statistically significant PFS benefit with capivasertib + abiraterone versus placebo + abiraterone. “The median rPFS of capivasertib + abiraterone was 33.2 months versus the placebo + abiraterone of 25.7 months (HR: 0.81, 95% CI: 0.66-0.98; p=0.034). Consistent benefits were also observed in secondary endpoints and clinically relevant pre-defined subgroups, but overall data were immature, and further follow-up is planned”.

Dr. Attard concluded with, “Capivasertib + abiraterone represents a potential first-in-class targeted treatment for patients with PTEN-deficient mHSPC.”

EMBARK

Dr. Murilo De Almeida Luz (US) presented the overall survival (OS) results from EMBARK, a randomised phase III trial of enzalutamide (enza) or placebo + leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer (HRBCR PCa). This trial began in 2014.

According to the trial results Dr. De Almeida Luz presented, the combination of enza + leuprolide reduced the risk of death by more than 40% versus leuprolide alone in patients with HRBCR PCa, and there was no evidence of metastasis on conventional imaging.

“Enza monotherapy led to numerically lower risk of death versus leuprolide alone, although the difference did not reach statistical significance. The trial results show that significant improvements in time to first use of the new antineoplastic therapy, time to symptomatic skeletal events, and PFS further highlight the benefit of both combining enza and monotherapy. The results show no new safety signals in the long-term safety analysis.”

—–

You can watch the full presentations, including the other ‘game-changing’ trials presented (CREST, ARASAFE, PACE B+C, and POTOMAC) via webcast recordings at the EMUC25 Resource Centre.

The post The big PCa game-changers for 2025 appeared first on EMUC25.

Session report: EMUC25 invokes mindset shift toward sustainability

“Healthcare is the fifth largest producer of greenhouse gases in the world” was a recurring claim in Plenary Session 1: Innovating for a sustainable future in genito-urinary cancer care: The road to 2050. The session featured sustainability in diagnosis and staging, as well as in treatments for radiation therapy, surgery, and medical oncology.

—-

Webcasts of the day

Kidney cancer – localised and locally advanced
RCC with venous thrombosis: optimal imaging for surgical planning and imaging-guided surgery
L. Bianchi, Bologna (IT)

Multidisciplinary case discussion: A stromal tumour in an unexpected location: Prostate
S.  Spohn, Freiburg (DE), R.  Flippot, Villejuif (FR), J.  Gómez Rivas, Madrid (ES), R.  Montironi, Ancona (IT), H.  Thoeny, Fribourg (CH)

—-

Session report on NMIBC: BCG failure, biomarkers and cost-effective treatments

Non-muscle invasive bladder cancer was featured in Plenary Session 4 today, with an insightful lecture from Dr. Chiara Mercinelli (IT) on ‘Failure after BCG systemic treatment”, Prof. Carmen Jeronimo (PT) presenting on “Urinary biomarkers for monitoring of NMIBC”, and Prof. Ashish Kamat (US) sharing the latest data review of the most cost-effective treatments for NMIBC failure.

—-

Photo impressions of the day

Check out our photo albums of Day 2 of EMUC25 and Abstract Award winners on Facebook. Share your photos and stories on Instagram, LinkedIn, and X as well.

—-

Best EMUC25 Abstracts

O07: Sasanlimab in combination with Bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non-muscle-invasive bladder cancer (HR NMIBC): Exploratory analysis of patients with very HR (VHR) disease from the phase 3 CREST trial
E.N. Xylinas, Paris (FR)

O05: Treatment with Oxaliplatin or Cisplatin in Combination with Gemcitabine ± Paclitaxel for Platinum-resistant Germ Cell Cancer: Results from a Multi-institutional Retrospective Study
C. Oing, Newcastle upon Tyne (GB)

O06: Association of Pathologic Response and Survival Outcomes in Muscle-Invasive Urothelial Cancer Following Different Neoadjuvant Therapies
Z. Myint, Lexington (US)

—–

EMUC25 Resource Centre

Missed a session? All webcasts, videos, posters and full-text abstracts EMUC25 are available via the Resource Centre.

For participants, viewing EMUC25 webcasts will also earn you CME accreditation. Webcasts are accredited up until Monday, 17 November 2025 (13:00 CET).

The post EMUC25: Day 2 highlights appeared first on EMUC25.

“BCG failure is defined as any high-grade disease occurring during or after BCG therapy” said Dr. Chiara Mercinelli (IT) in her lecture on ‘Failure after BCG systemic treatment”. How does this happen? According to Dr. Mercinelli, BCG treatment increases the expression of PD-L1, Tregs, and tumour-associated macrophages, creating an immunosuppressive microenvironment over time. “This PD-L1 upregulation is one of the key mechanisms of immune escape and ultimately explains why some patients become BCG-unresponsive.”

What are the options? Dr. Mercinelli shared the key results of several novel therapies, before summarising these key take-home messages:

• Systemic checkpoint inhibitors restore T-cell function and can enhance or complement the anti-tumour activity of intravesical agents.
• Pembrolizumab is already FDA-approved for CIS BCG-unresponsive, confirming a clinical role for systemic therapy (complete clinical response at 6 months: 36%).
• Trials combining local and systemic therapy (CG0070 + pembrolizumab) show the highest clinical response rates in early-phase trials. Targeted therapy is a valid approach in the NMIBC population.
• Robust randomised trials to compare intravesical and systemic versus intravesical alone are urgently needed to define optimal sequencing and combination strategies.

Prof. Carmen Jeronimo (PT) presented on “Urinary biomarkers for monitoring of NMIBC”. She noted that NMIBC represent the majority of all bladder cancers and have a high recurrence (up to 70%) and variable progression (up to 20%), necessitating life-long surveillance. In her opinion, biomarkers offer the potential to reduce unnecessary cystoscopies and anticipate the identification of high-risk patients in NMIBC. “Urinary biomarkers are ideal for risk-adaptive surveillance – balancing patient burden and recurrence detection.”

She emphasised the need for further validation of the best-performing biomarkers in diverse real-world settings (different populations, different hospitals) and their implementation in clinical practice. She also highlighted that combing biomarker panels with AI driven multimodal surveillance could help individualise NMIBC follow-up.

What is the most cost-effective treatment in NMIBC failure?

According to Prof. Ashish Kamat (US), current options for patients in NMIBC failure are extensive and include immunotherapies, chemotherapy, a combination of both, gene therapies, targeted therapies, device-assisted therapies, and radiotherapy plus immunotherapy. But patients face many treatment considerations, including short-term cure versus short-term gain, quality of life, logistical challenges, anxiety, potential long-term side effects from drugs, and financial toxicity.

Prof. Kamat shared new research (Myers, Talwar et al. 2025) assessing the financial toxicity of five treatments: radical cystectomy, nadofaragene, nogapendekin/BCG, pembrolizumab and gemcitabine/docetaxel, as well as the study CISTO (Gore J, et. al 2025) on the financial impact of bladder-sparing therapy versus radical cystectomy.

He concluded that cost-effectiveness varies by treatment strategy and patient goals, but radical cystectomy remains the most cost-effective overall. Among bladder-sparing therapies, gemcitabine/docetaxel is the most-cost effective single-line option. He noted that multiple sequential therapies offer limited (financial) value, and in his final in comment he stressed that shared decision making is as important as ever.

Visit the EMUC25 Resource Centre to see their full presentations.

The post Strategies in NMIBC: BCG failure, biomarkers and cost-effective treatments appeared first on EMUC25.

The patient was a 44-year-old female who had left-back pain, a 10 cm left kidney mass, 3.5 cm para-aortic mass, and multiple liver lesions. Fine-needle aspiration (FNA) and formalin-fixed paraffin-embedded (FFPE) cell block were performed before the operation. Presurgical therapy was applied, then the tumour was resected. The results showed it was post-therapy favourable (no anaplasia), high-risk (blastemal predominant) triphasic WT. The Children’s Oncology Group (COG) stage was IV (hematogenous metastases).

Prof. Montironi stated that WT in adult patients is a difficult and unexpected diagnosis, whereas RCC is the most difficult kidney tumour. In an adult patient, there is a much broader differential diagnosis, requiring significant additional ancillary testing to consider other possibilities, based on FNA findings and immunohistochemical and molecular studies.

Prof. Montironi enumerated the most helpful pathologic features when using FNA to diagnose WT in adult patients:

1. Malignant epithelioid cells with tubular and rosette-like architecture
2. Frequent mitotic figures
3. Necrosis
4. WT1 expression by immunohistochemistry

“The FNA in adult patients can be a bit tricky because there are lesions that can mimic [other tumours] or are difficult to diagnose. One of these is a metanephric adenoma, which is related to WT. Some authors would refer to it as the benign counterpart or the beginning of WT. We have to identify the criteria for malignancy, such as the presence of a blastemal component, mitosis, and necrosis. These indicate WT,” said Prof. Montironi.

According to him, from the morphological point of view, histology in pediatric and adult patients is identical. “The components represent stages in normal or abnormal nephrogenesis. There are undifferentiated blastemal cells, and also cells differentiating towards epithelial and stromal elements. We see three patterns, which means they are triphasic. If there are two, it is biphasic, and sometimes, it’s monophasic, which can be more difficult to diagnose.”

For more information on the patient case and WT, (re)watch the Prof. Montironi’s full presentation on the EMUC25 Resource Centre.

Medical oncologist Asst. Prof. Ronan Flippot (FR), urologist Prof. Juan Gómez Rivas (ES), pathologist Prof. Rodolfo Montironi (IT), radiotherapist Dr. Simon Spohn (DE), and radiologist Prof. Harriet Thoeny (CH) led Plenary Session 3.

The post Wilms tumour in adults? appeared first on EMUC25.

Sustainable diagnosis and staging
In his presentation “Sustainable diagnosis and staging,” Prof. Veeru Kasivisvanathan (GB) outlined key sustainability principles, including “use less” (reduce waste and minimise unnecessary consumption), “use longer” (extend the lifespan of existing products), and “use greener” (adopt more environmentally friendly alternatives).

In urothelial diagnostics, sustainability in patient selection includes optimising secondary-care referrals. From a diagnostic perspective, key measures include establishing one-stop haematuria clinics, decarbonising flexible cystoscopy (for example, avoiding sterile cystoscope drapes by placing the scope on the decontamination storage tray and omitting hospital gowns), performing flexis in the clinical setting, minimising the use of CT urograms, and implementing same-day preoperative assessment.

Regarding sustainability in prostate cancer (PCa) diagnostics, Prof. Kasivisvanathan emphasised selecting patients at the highest risk of harbouring clinically significant PCa for imaging or biopsy. He added to avoid the diagnosis of clinically significant cancer; reduce the risk of complications to patients; and to use imaging and biopsy appropriately to ensure high-quality outcomes. He also noted that optimising imaging departments—such as by switching off unused electronic devices and PACS systems—can yield substantial environmental benefits, with the latter alone capable of saving an estimated 51.2 tonnes of CO₂ annually.

On radiation therapy (RT)

Radiation oncologist Dr. David Hunt (GB) discussed hypofractionation as a sustainable alternative to standard RT during his presentation “Sustainable treatments: Radiation therapy”. Hypofractionation is when the total dose of radiation is divided into large doses, and treatments are given less often.

Dr. Hunt addressed the audience and said, “To the leaders in the room, we need you to champion high-impact change in terms of how we run, build, and deliver, and empower healthcare services. We need your voices to be loud to drive improvements within the industry where we’re making big decisions in the procurement of equipment and [to encourage] the development of more sustainable, durable, and efficient devices.”

To fellow radiation oncologists, he stated, “You can make the biggest difference today. Adopt the evidence-based hypofractionated radiotherapy, such as in the PACE B protocol. Participate in and await trial data from other hypofractionation trials. Read and/or implement guidelines.”

Dr. Hunt urged the rest of the audience to make every treatment count. “I hope you’ll take something away from today’s Plenary Session. May it inspire you to think about what you can do not just for the workplace. No one’s going to make healthcare sustainable for us. It has to come from within.”

On surgery

“25% of hospital waste comes from the OR,” stated Dr. Benjamin Pradère (FR), who shared the “climate-smart actions”: sustainability, reduce waste, recycle, reuse, and reduce energy consumption in his presentation “Sustainable treatments: Surgery”.

According to Dr. Pradère, education for segregation is key. Most of the waste can be considered as regular/uncontaminated waste. He underscored the importance of proposing dedicated recycling facilities for segregation. He added that preoperative waste comes from the devices used, and that there is an urgent need for recycling programmes and other manufacturing/packaging modifications.

Dr. Pradère provided examples of more sustainable practices in surgical care. He noted that spinal anaesthesia produces 67 times less greenhouse gas (GHG) emissions compared to general anaesthesia. He discussed the advantages and disadvantages of reusable products (i.e., regarding endoscopic instruments). He encouraged combating planned obsolescence by powering down consoles and streamlining data management. Separating waste generated before the operating room from intraoperative waste was associated with a 50% reduction in annual waste output. He also promoted performing TURBT procedures in ambulatory settings. He added to favour oral postoperative treatments.

According to Dr. Pradère, energy consumption is the largest source of GHG emissions in the surgical environment; thus, reducing the use of heating, ventilation, and air-conditioning systems and powering operating rooms with clean energy were recommended strategies.

On medical oncology

Some of what medical oncologist Prof. Yüksel Ürün (TR) discussed in his presentation “Sustainable Treatments: Medical oncology” were the exploration of the clinical, economic, environmental, and social dimensions of sustainable genitourinary (GU) cancer care. Clinically, he emphasised the importance of smarter trials, leveraging real-world data, treatment de-escalation, and shorter therapy durations. From an economic perspective, he highlighted value-based care and outcome-linked pricing. On the environmental front, he discussed initiatives such as green hospitals, renewable energy, reducing drug waste, and sustainable supply chains. Socially, he underscored the need for diversity in clinical trials and empowering patients as co-creators in their care.

Medical oncologist Dr. Elena Castro (ES), nuclear medicine physician Prof. Dr. Karolien Goffin (BE), urologist Dr. Laurence Klotz (CA), and radiation oncologist Prof. Thomas Zilli (CH) spearheaded the Plenary Session.

(Re)view all their presentations via the EMUC25 Resource Centre.

The post EMUC25 invokes mindset shift toward sustainability appeared first on EMUC25.

Session report: The future of finding cancer

“Without the right clinical question, even the best technology is useless,” said Prof. Konrad Stock (DE), opening a discussion on whole-body MRI (WB-MRI) as a screening tool in healthy individuals. Read this report featuring lectures by Profs. Grant Stewart (GB), Laurence Klotz (CA), and Giuseppe Petralia (IT) on the future directions in early cancer detection.

______

Webcasts of the day

Watch the introduction of the patient case here by A. Van Der Heijden, Nijmegen (NL).

Imaging Plenary Session 3
Rapid case debate: Cystectomy without TURBT
Yes, we can
J. D. Kelly (GB)

Imaging Plenary Session 3
Rapid case debate: Cystectomy without TURBT
No, it’s madness
M. Rouprêt, Paris (FR)

______

Session report: SPARC, APCCC, and a new RCC tracer

What are the conclusions of the Standardised PSMA PET Reporting Concensus (SPARC)? Are there disparities in the Advanced Prostate Cancer Consensus Conference (APCCC) diagnostics? What is the latest tracer in the diagnosis of kidney cancer? Led by the Chair of the EAU Section of Urological Imaging, Prof. Francesco Sanguedolce (ES), together with nuclear medicine physician, Prof. Karolien Goffin (BE), the “Joint Session of the EAU Section of Urological Imaging and European Association of Nuclear Medicine” provided insights into these questions.

______

Photos and Imaging Abstract Award Winners

Check out our photo albums of Day 1 of EMUC25 and Abstract Award winners on Facebook. Share your photos and stories on Instagram, LinkedIn, and X as well.

______

Best imaging abstracts

LBO01: Impact of Initial PSMA-PET/CT Staging and PSMA-Targeted Biopsies on Treatment Decisions in Prostate Cancer: Results from the Phase II DEPROMP Trial
P. Krausewitz, Bonn (DE)

O08: The RING study: A European registry of next-generation imaging in advanced prostate cancer – protocol and preliminary findings
D. Chernysheva, Tashkent (UZ)

O12: A retrospective study of the diagnostic performance of CT urography vs. ureterorenoscopy in the follow-up setting of kidney-sparing surgery for upper tract urothelial carcinoma
O. Figaroa, Amsterdam (NL)

______

EMUC25 Resource Centre

Missed a session? All webcasts, videos, posters and full-text abstracts EMUC25 are available via the Resource Centre.

For participants, viewing EMUC25 webcasts will also earn you CME accreditation. Webcasts are accredited up until Monday, 17 November 2025 (13:00 CET).

The post Highlights from Day 1 at EMUC25 appeared first on EMUC25.